A statement from Gilead indicates that the deal is likely to lower its 2025 GAAP and non-GAAP earnings per share by $0.15 to $0.17. While Gilead may earn royalties on topical formulations, LEO Pharma ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of the latter’s small molecule oral signal transducer and activator of ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

Gilead Sciences Inc. and LEO Pharma have partnered to accelerate the development and commercialization of LEO Pharma’s small ...

Gilead licenses Leo Pharma's oral STAT6 portfolio for inflammatory diseases in $250M upfront deal, potentially worth $1.7B, ...

As we enter January 2025, global markets have been marked by volatility, with small-cap stocks underperforming and inflation concerns persisting amid a resilient U.S. labor market and political ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

The exosome therapies market is expected to experience significant growth due to increased interest in regenerative medicine, ...

The Cebu provincial government is preparing four initial cases against the National Museum of the Philippines (NMP) for still not returning the four pulpit panels to the Archdiocesan Shrine of ...

To date, Comcast has increased its dividend for 17 consecutive years, with a 10-year dividend growth rate of 10.9%. Read more ...

India News Live: Stay informed with our live blog covering India’s latest in politics, economy, crime, and general news. Get real-time updates on political developments, financial trends, crime ...

ON CRISPR enzyme, will combine with RNA guides for pharma customers. Deal follows HuidaGene agreement, offers 99% cost ...